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Abstract
Articular cartilage disorders and injuries often result in 
life-long chronic pain and compromised quality of life. 
Regrettably, the regeneration of articular cartilage is 
a continuing challenge for biomedical research. One 
of the most promising therapeutic approaches is cell-
based tissue engineering, which provides a healthy 
population of cells to the injured site but requires dif-
ferentiated chondrocytes from an uninjured site. The 
use of healthy chondrocytes has been found to have 
limitations. A promising alternative cell population is 
mesenchymal stem cells (MSCs), known to possess 
excellent proliferation potential and proven capability 
for differentiation into chondrocytes. The “immunosup-
pressive” property of human MSCs makes them an 
important candidate for allogeneic cell therapy. The use 
of allogeneic MSCs to repair large defects may prove to 
be an alternative to current autologous and allogeneic 
tissue-grafting procedures. An allogeneic cell-based 
approach would enable MSCs to be isolated from any 
donor, expanded and cryopreserved in allogeneic MSC 
banks, providing a readily available source of progeni-
tors for cell replacement therapy. These possibilities 
have spawned the current exponential growth in stem 
cell research in pharmaceutical and biotechnology com-
munities. Our objective in this review is to summarize 
the knowledge about MSCs from umbilical cord stroma 
and focus mainly on their applications for joint patholo-
gies.
© 2011 Baishideng. All rights reserved.
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INTRODUCTION AND JUSTIFICATION
Mesenchymal stromal cells or mesenchymal stem cells 
(MSCs) are a plastic-adherent cell population that ex-
presses specific surface markers and have the capacity to 
self-renew and differentiate into bone, cartilage, adipose, 
muscle and neural cells in adequate conditions[1-3]. MSCs 
are found in a variety of  tissues, including the umbilical 
cord[4-6], which is the focus of  this review and provides a 
non invasive source of  abundant stem cells. MSCs are a 
relatively new source for cell therapy for cartilage and sur-
rounding joint tissues. Regenerative therapies for cartilage 
defects will profit greatly from the combined applications 
of  available basic science knowledge of  matrix biology, 
hormone and receptor biology, biomechanics, virology, 
scaffolds and transplantation medicine[7]. Although the 
therapeutic potential of  MSCs is being studied and has 
clear objectives, the requirements and conditions for their 
direct chondrogenic differentiation in vitro remains a chal-
lenge. This review is intended to summarize our knowl-
edge of  umbilical cord MSCs, including their derivation 
from Wharton’s jelly or umbilical cord blood and their 
therapeutic application for joint pathologies. 
UMBILICAL CORD MSCS
MSCs have been isolated from umbilical cord blood, um-
bilical vein subendothelium and Wharton’s jelly cells. All 
these cells are a primitive stromal population that displays 
the characteristics of  MSCs defined by the International 
Society for Cellular Therapy. Umbilical cord MSCs grow 
as adherent cells with mesenchymal morphology, are self-
renewing, express cell surface markers typical of  MSCs 
(CD14-, CD34- and CD45-negative while expressing 
high levels of  CD73, CD90 and CD105), maintain their 
differentiation potential and can differentiate in vitro into 
various cell lineages, including bone, cartilage and adipose 
tissue[8]. Umbilical cord MSCs also have the capacity to 
form neurons and glia in vitro[9] and can be successfully 
trans-differentiated into cardiomyocytes in vitro[10]. Like 
other stromal cells, MSCs derived from the umbilical cord 
support the expansion of  other stem cells, such as hemat-
opoietic stem cells, and are well-tolerated by the immune 
system[11]. Human umbilical cord MSCs share similar 
in vitro immunosuppressive properties with MSCs obtained 
from bone marrow and blood. However, the mechanisms 
and cell interactions used by MSCs to control immune re-
sponses are not yet fully elucidated[12]. Functional module 
analysis has shown different osteogenic potential and dif-
ferentiation capacity for human MSCs from bone marrow 
and Wharton’s jelly[13]. There are no known limitations to 
using umbilical cord–derived MSCs. Wu et al[14] published 
the first report of  umbilical cord MSCs in a human clini-
cal application. They found that umbilical cord MSCs 
had superior proliferative potential and more suppressive 
effects on peripheral blood mononuclear cell prolifera-
tion than bone marrow MSC. The acute graft-versus-host 
disease improved dramatically after each of  four infusions 
of  umbilical cord MSCs into the two patients. No adverse 
effects were noted. Both patients are doing well now and 
this procedure seems both feasible and safe. 
Umbilical cord blood
Several studies of  MSCs derived from the umbilical cord 
blood of  several species show them to be capable of  be-
ing isolated and differentiated toward defined mesoderm 
lineages. Included in these species are equine[15,16], ca-
nine[17], porcine[18], ovine[19] and human[20,21]. Studies have 
also focused on the ability of  umbilical cord MSCs to 
support the ex-vivo expansion of  other cell types and their 
differentiation into other lineages[22,23]. Recent studies by 
Kim et al[24] have examined the molecular mechanism of  
differentiation, such as the involvement of  NOD1 and 
NOD2 for differentiation of  MSCs derived from human 
umbilical cord blood, and analyzed the ability of  these 
cells to function as alloantigens in vitro. Current results in-
dicate that human umbilical cord blood-derived MSCs do 
not provoke allogeneic peripheral blood mononuclear cell 
proliferation even when their HLA-molecule expression 
was up-regulated by interferon-(IFN)-γ pre-treatment. 
This suppressive effect was mediated by soluble factors. 
Overall it seems that MSCs from umbilical cord blood 
can suppress the allogeneic response of  lymphocytes and 
may prove useful in allogeneic cell therapies[25]. Umbilical 
cord blood is a valuable source for hematopoietic pro-
genitor cell therapy. It also contains another non-hemat-
opoietic cell population, mesenchymal progenitor cells 
(MPCs), which can be expanded ex vivo and differentiated 
into osteoblasts, chondrocytes and adipocytes. Several 
studies[4,26] indicate that two sub-populations of  MSCs 
can be isolated from umbilical cord blood by using spe-
cific methods. These cells exhibit different morphological 
phenotypes, the majority of  which resemble flattened 
fibroblasts and the remainder spindle-shaped fibroblasts. 
Both MSC types share similar cell surface markers, except 
for CD90, and have similar osteogenic and chondrogenic 
potential. The spindle-shaped population is positive for 
CD90 and shows more capability for adipogenesis, while 
the flattened cell type is CD90 negative and shows less 
capability for adipogenesis. The larger number of  flat-
tened umbilical cord blood MPCs might be linked to 
their lowered capability for adipogenic differentiation[27].
Wharton’s jelly
The number of  studies of MSCs derived from stromal 
tissues has increased over the last 6 years. However, these 
cells have not been as widely studied as MSCs derived 
from umbilical cord blood. Can et al[28] described the 
noninvasive isolation, culture and basic characterization 
of  human umbilical cord stroma -MSCs. MSCs derived 
from Wharton’s jelly were isolated using their adherence 
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to plastic and characterized by flow cytometry, looking for 
cells positive for STRO1, OCT3/4 and SSEA-4, as well as 
those positive for the classic MSC-markers, CD44, CD73, 
CD90, Ki67, CD105 and CD106, and negative for CD34 
and CD45[29-32] (Figure 1). These MSCs were differentiated 
towards musculoskeletal tissue[33] and CD10 positive cells 
that displayed contractile properties[34]. Wharton’s jelly 
MSCs are also candidates for β cell regeneration, utilizing 
their immune response inhibiting benefits for treatment 
of  type 1 diabetes[35]. Wharton’s jelly-derived MSCs may 
prove to be a better clinical alternative to bone marrow-
derived MSCs because of  their ease of  access, higher 
expansion potential and low immunogenicity. The use 
of  allogenic MSCs would be possible in vivo only if  they 
retain their immune properties in an inflammatory envi-
ronment. Thus, the focus of  a study by Prasanna et al[36] 
sought to understand and compare the immune proper-
ties of  MSCs from Wharton’s jelly and from bone marrow 
primed with the key pro-inflammatory cytokines, IFN-γ 
and tumor necrosis factor α. Importantly, these authors 
found that inflammation affects the immune properties 
of  these MSCs differently and that MSCs derived from 
different tissues may utilize different unique mechanisms 
of  immune-modulation. 
Recent studies by Huang et al[37] have demonstrated 
that MSCs can differentiate into germ cells under ap-
propriate conditions. MSCs were induced to differentiate 
into germ cells in all-trans retinoic acid, testosterone and 
testicular-cell-conditioned medium prepared from new-
born male mouse testes. These MSCs formed “tadpole-
like” cells after induction with different reagents and 
showed both mRNA and protein expression of  the 
germ-cell-specific markers, Oct4 (POUF5), Ckit, CD49 
(f) (α6), Stella (DDPA3) and Vasa (DDX4). These re-
sults could lead to a new reproductive therapy utilizing 
human umbilical cord MSCs as well as provide a novel 
in vitro model for investigating the molecular mechanisms 
regulating development of  the mammalian germ cell line-
age[37]. Proteomic analyses of  human MSCs from Wharton’
s jelly during in vitro expansion have demonstrated their 
potential capacity for self-renewal and in vitro expansion[38]. 
More than 30% of  158 proteins identified by these analy-
ses belong to the cytoskeleton complex. However, several 
proteins were no longer expressed after the 2nd in vitro pas-
sage, suggesting the proliferative potency of  these cells was 
reduced after the initial in vitro stage. This important study 
provides an essential step for gaining an understanding of  
the molecular properties of  Wharton’s jelly cells[38].
Obstetric parameters, including the gender of  the 
baby, birth weight, the age of  the mother at delivery, ges-
tational stage at parturition and mode of  delivery were 
examined by Penolazzi et al[39] who found that osteoblastic 
potential was not influenced by the baby’s gender and 
mode of  delivery. The highest degree of  osteoblastic po-
tential was shown by MSCs from Wharton’s jelly selected 
from the heaviest full-term babies and with high basal lev-
els RUNX-2. The results of  this study are helpful to select 
optimal umbilical cord donors for efficiently collecting 
high potential Wharton’s jelly-derived osteoprogenitors. 
Therefore, the isolation and culture of  human umbilical 
cord-MSCs still need better clarification to ultimately build 
an optimal standard procedure among laboratories, tissue 
banks and clinics.
UMBILICAL CORD MSCS AND 
CHONDROGENESIS
MSCs from equine umbilical cord blood produced a tis-
sue with a cartilage-like morphology that stained positive 
for proteoglycans and expressed typical cartilage mark-
ers[40]. These authors found that MSCs from umbilical 
cord blood possessed more chondrogenic potential than 
bone marrow-derived MSCs, based on the cell popula-
tions tested and parameters measured[40]. Another study 
using canine MSCs from umbilical cord blood employed 
osteogenic and chondrogenic differentiation detected 
by alizarin red and toluidine blue staining respectively[17]. 
With osteogenic differentiation, the MSCs were shown 
to express osteoblastic differentiation genes by reverse 
transcriptase-polymerase chain reaction (RT-PCR). The 
results from this study suggest that canine MSCs are ca-
pable of  multipotential differentiation[17]. 
MSCs from porcine umbilical cord blood were iso-
lated and their morphology, proliferation, cell cycle 
status, cell-surface antigen profile and expression of  
hematopoietic cytokines characterized by Kumar et al[18]. 
The capacity of  porcine MSCs to differentiate in vitro into 
osteocytes, adipocytes and chondrocytes was also evalu-
ated. These investigators found that the expression of  
lineage-specific genes was gradually up-regulated during 
osteogenesis, adipogenesis and chondrogenesis. Porcine 
umbilical cord blood also contains a population of  MPCs 
capable of  self-renewal and of  differentiating in vitro into 
three classical mesenchymal lineages. 
The in vitro growth of  human umbilical cord blood 
MSCs has been achieved; their differentiation into 
chondrocytes and osteoblasts demonstrates their multipo-
tentiality and predisposition towards a mesodermal fate[41]. 
Wharton’s jelly contains mucoid connective tissue and 
fibroblast-like cells. Using flow cytometric analysis, Wang 
et al[29] found that mesenchymal cells isolated from hu-
man Wharton’s jelly express the matrix receptors CD44 
and CD105, plus integrin markers CD29 and CD51, but 
not the hematopoietic lineage markers CD34 and CD45 
(Figure 2). Interestingly, these cells also express significant 
amounts of  the MSC markers SH2 and SH3[29]. Isolated 
and characterized MSCs from human umbilical cord stro-
ma and quantitative RT-PCR analysis of  the genes ALP, 
MEF2C, MyoD, LPL, FAB4 and AMP, characteristic for 
the differentiated lineages, were used to evaluate early and 
late differentiation of  three germ lines[30]. Direct chondro-
genic differentiation was achieved by utilizing spheroid 
formation by MSCs in a chondrogenic medium; testing 
for the presence of  chondrogenic markers was done at 
4, 7, 14, 28 and 46 d of  culture. Immunohistochemistry 
and quantitative RT-PCR analyses were employed to as-
sess the expression of  collagen type 1 (COL1), collagen 
type 2 (COL2) and collagen type X (COLX) at the times 
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Figure 1  Characterization of the mesenchymal stem cell population from human umbilical cord stroma. A: Flow cytometry of the principal mesenchymal stem 
cell (MSC) markers. In each diagram, at the top is the name of the marker, at the bottom the fluorochrome used and at the top right the percentage of positive cells; B: 
Immunofluorescence analysis of CD44 and CD90 in a human umbilical cord cryosection; DAPI was used to label cell nuclei. (Magnification 20 ×); C: Alizarin red stain 
(upper) and Oil red O stain (lower) of spheroids engineered from MSCs differentiated in two defined media, proving their pluripotency. OM: Osteogenic medium; AM: 
Adipogenic medium; DMEM: Control medium with no defined cytokines to promote differentiation.
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studied[30]. These investigators found expression of  all 
chondrogenic markers as early as 4 d of  chondrogenic dif-
ferentiation culture, with their expression increasing with 
time except for COL1 which decreased in expression in 
the formed spheroids after 4 d of  differentiation. A secre-
tome study to validate this model for in vitro chondrogenic 
differentiation was performed using the spheroids formed 
during the chondrogenesis process[30]. The results summa-
rized in Figures 1 and 2 indicate the multipotential capac-
ity of  human MSCs from this source; their chondrogenic 
capacity may prove useful for future cell therapies for 
articular diseases[30]. It would also be interesting to see if  
the chondro-type tissues being differentiated from these 
MSCs can be modified in vitro using biomaterials or other 
factors to mimic the 5 different layers observed in normal 
cartilage but it is too early in the research to know this and 
there is no report of  it in the literature.
THERAPEUTIC APPLICATION OF 
UMBILICAL CORD MSCS FOR JOINT 
PATHOLOGIES
Human MSCs, with particular reference to Wharton’s 
jelly MSCs, have an important role as immunomodula-
tors and their multilineage differentiation potential makes 
their use in tissue regeneration and repair possible[42].
Although bone marrow represents the primary avail-
able source of  MSCs, the use of  bone marrow-derived 
cells is not always acceptable because of  their high degree 
of  viral infection and the significant drop in cell number 
and both proliferative and differentiation capacity with 
ageing. Romanov et al[43] isolated MSCs from the suben-
dothelial layer of  the umbilical cord and found that cord 
vasculature contains many MSC-like elements forming 
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colonies of  fibroblastoid cells that express several mesen-
chymal cell markers and can be successfully expanded in 
culture. They proposed that umbilical cord/placenta stro-
ma may become an alternative source of  MSCs for exper-
imental and clinical needs[43]. Scaffolds provide a template 
for cell distribution, growth, differentiation and extracel-
lular matrix accumulation in three dimensions. Recent 
studies[44,45] have demonstrated the potential of  scaffold-
ing to enhance articular cartilage repair both in vitro and 
in vivo. Kao et al[46] demonstrated that chemically syn-
thesized thermoreversible gelation polymer provided a 
competent three-dimensional culture environment for 
cord blood MSCs to differentiate into chondrocytes and 
may prove to be clinically useful to induce chondrogenic 
differentiation of  MSCs from cord blood for cartilage re-
pair. Although bone marrow was the first reported source 
to contain MSCs, obtaining and utilizing these MSCs is 
not always practical due to the very invasive technique 
required for drawing them and the decline in cell number 
and differentiation capability with increasing age. 
Mononuclear cells derived from human umbilical 
cord blood and obtained by a negative immunoselection 
technique exhibited either osteoclast-like or mesenchy-
mal-like phenotypes[47]. However, these cells were able to 
produce homogeneous populations of  MSCs displaying 
a fibroblast-like morphology while expressing mesen-
chyme-related antigens and showing differentiation capa-
bility for osteoblastic and early chondroblastic lineages. 
This study by Barachini et al[47] is one of  the few investi-
gating human umbilical cord blood-derived MSC growth 
and differentiation on three-dimensional scaffolds. The 
potential applications in regenerative medicine and tis-
sue engineering of  umbilical cord blood-derived MSCs 
were illustrated by their ability to grow on biodegradable 
microfiber meshes and their capability to differentiate 
into mature osteoblasts when cultured inside human 
plasma clots; this suggests their potential applications in 
orthopedic surgery. In a 6 wk study by Wang et al[48], a 
comparison of  chondrogenic differentiation of  human 
bone marrow MSCs and human umbilical cord MSCs in 
a three-dimensional scaffold was conducted for the first 
time. Cells were seeded on polyglycolic acid scaffolds at 
25 M cells/mL and cultured in identical conditions. Cell 
proliferation, biosynthesis and chondrogenic differentia-
tion were assessed at weeks 0, 3 and 6 after seeding. The 
authors concluded that human umbilical cord MSCs 
might provide a desirable option for use as a mesenchy-
mal cell source for fibrocartilage tissue engineering, based 
on the abundant COL1 and aggrecan production of  hu-
man umbilical cord MSCs in a three-dimensional matrix. 
Further investigations of  the optimal signals to promote 
COL2 production from human umbilical cord MSCs are 
necessary for their use in hyaline cartilage engineering.
MSCs from Wharton’s jelly have been shown to be 
therapeutic in several pre-clinical animal models for 
neurodegenerative disease, cancer, heart disease, etc. The 
preclinical work suggested that MSCs from Wharton’s 
jelly are therapeutic by mechanisms of  trophic rescue and 
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Figure 2  Representative diagrams of the methodology for spheroid chondrogenesis. Diagram showing culture times used for a new method for the induction 
of chondrogenesis. Representative sections of immunohistochemical analyses for collagen type 2 (COL2) expression from spheroids engineered from Wharton´s jelly 
mesenchymal stem cells at different times of chondrogenesis are shown. (Magnification 10x). AA: Ascorbic acid; MTG: Monothioglycerol; RA: Retinoic acid; KO se-
rum: Knock out serum (GIBCO™); TGFβ-3: Recombinant human transforming growth factor-β3; TRANS: Transferrine; DEX: Dexamethasone.
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immune modulation. MSCs from human Wharton’s jelly 
represent a promising source for progenitor cells with the 
potential to repair and regenerate solid tissues[49]. Collagen-
embedded MSCs from Wharton’s jelly have a homogenous 
growth pattern as well as a constant expression of  growth 
factors and extracellular matrix proteins without any nega-
tive effects on the epidermal layer, as shown by histology, 
electron microscopy, immunohistochemistry and real 
time-RT-PCR. These results indicate the necessity for an 
organizing a biomaterial-based scaffold to direct stem cell 
differentiation, proliferation and paracrine activity, as well 
as regulation of  extracellular matrix deposition[50,51].
Preliminary in vitro studies done in our group have 
shown some degree of  differentiation and integration of  
MSCs from Wharton’s jelly into a human osteochondral 
punch (Figure 3). Further work is needed to determine 
whether the Wharton’s jelly MSCs can engraft in vivo over 
the long term and can self-renew cartilage. There are several 
studies[52] using acellular umbilical veins seeded with MSCs 
from bone marrow to engineer tendon but umbilical cord-
derived MSCs have not yet been tested for this purpose. 
New research studies[53,54] involving the use of  new 
scaffold materials made from hyaluronic acid, collagen 
and other extracellular matrix proteins should be men-
tioned. These extracellular matrix scaffolds have been 
used to create three-dimensional structures for support-
ing in vitro growth and chondrogenesis of  MSCs and their 
possible clinical use for the replacement of  damaged 
joints[51,55-57]. To date, all these studies have utilized only 
MSCs from bone marrow and none of  them have con-
sidered the dangerous aspects of  such tissue-like induct-
ing malignancies.
In summary, umbilical cord MSCs are multipotent 
stem cells that may serve many therapeutic and biotech-
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Figure 3  Cellular therapy. A: Graphic illustrating the regeneration of a chondral lesion in vitro; B: Wharton’s jelly mesenchymal stem cells (MSCs) growing in vitro in a 
human osteochondral punch lesion over 90 d in chondrogenic medium with added transforming growth factor β3. Modified Masson staining shows the MSCs differenti-
ating in the lesion (Magnification 2 ×, 4 × and 20 ×); C: Graphic portraying the technique of intra-articular injection of MSCs into an injured joint to treat lesions in vivo.
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nological roles in cartilage repair opportunities. Consider-
ing that acquiring umbilical cord derived-MSCs is a non 
invasive technique, these cells would appear to be the 
ideal candidates for clinical cell-based therapies. It would 
appear to be promising news for use in future in vivo 
studies and consequently clinical trials for cartilage repair 
therapies. Successful in vitro and in vivo differentiation to 
several lineages makes these cells an invaluable stem cell 
source, deserving further testing as a cellular therapy or 
other applications in regenerative medicine. 
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